Nuwellis (NUWE) Appoints Mike McCormick as CEO
Mike McCormick becomes chief executive of the medical technology company effective June 30, 2026, replacing John Erb, who transitions to chairman.
By the FiledFeed automated desk
This summary was generated by AI from the company's SEC filing and may contain errors — always verify against the primary source on SEC.gov.
The short version
Nuwellis has appointed Mike McCormick as Chief Executive Officer, effective June 30, 2026. John Erb, the current President, CEO, and Chairman, will step down from his executive role but remain as Chairman. McCormick is a veteran medical device executive who served on Nuwellis's board from June 2023 through January 2026.
Filing impact
Filing sentiment
Nuwellis, Inc., a medical technology company focused on treating patients with heart and kidney conditions, announced on June 16, 2026, that it has appointed Mike McCormick as Chief Executive Officer, effective June 30, 2026.
John Erb, who currently serves as President, CEO, and Chairman of the Board, will step down from his executive leadership role but will remain with the company as Chairman of the Board.
McCormick brings more than 30 years of experience in the medical device industry, including founding and leading both public and private healthcare companies. He previously served as an independent board member at Nuwellis from June 2023 through January 2026. His background includes expertise in product development, commercialization, corporate strategy, and business growth.
In a statement, Erb said McCormick's operational leadership, commercial expertise, and deep understanding of the medical device industry made him well-suited to lead the company's next phase of growth. McCormick said he is focused on expanding precision fluid management solutions in heart and kidney care and strengthening the company's commercial execution and pipeline.
Nuwellis develops technologies designed to monitor and treat complex heart and kidney conditions across hospital and long-term care settings.
Key facts
- Nuwellis (NUWE) appointed Mike McCormick as Chief Executive Officer, effective June 30, 2026
- John Erb transitions from CEO and President to Chairman of the Board
- McCormick has over 30 years of experience in medical device leadership
- McCormick previously served on Nuwellis's board from June 2023 through January 2026
- Nuwellis is a medical technology company focused on cardiorenal (heart and kidney) conditions
- Announcement filed June 17, 2026 via 8-K (material disclosure form)
Why it matters
Leadership transitions at medical device companies can signal a shift in strategic direction or operational focus. McCormick's appointment represents continuity on the board (he was already a director) while bringing in an experienced operator to lead the company's commercialization and pipeline execution. Erb's move to the chairmanship rather than full departure suggests a structured handoff rather than a forced change. For investors, this is a clear governance event—the succession plan and backgrounds of both executives are visible, though the market impact will depend on investor confidence in McCormick's ability to accelerate growth and capital efficiency at Nuwellis.
Frequently asked
- When does Mike McCormick become CEO of Nuwellis?
- Mike McCormick becomes Chief Executive Officer effective June 30, 2026.
- What happens to current CEO John Erb?
- John Erb steps down from his roles as President and CEO, but remains with the company as Chairman of the Board.
- What is Mike McCormick's background?
- McCormick is a seasoned medical device executive with over 30 years of experience spanning product development, commercialization, corporate strategy, and leading both public and private healthcare companies. He previously served as an independent board member at Nuwellis from June 2023 through January 2026.
- What does Nuwellis do?
- Nuwellis is a medical technology company that develops solutions for patients with cardiorenal (heart and kidney) conditions, with a focus on monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings.
What the filing reported
- 5.02 Departure/Election of Directors or Officers
- 7.01 Regulation FD Disclosure
- 9.01 Financial Statements & Exhibits
Source
Based on Nuwellis, Inc.'s 8-K filed with the SEC on Jun 17, 2026. Read the original filing on SEC.gov ↗